Needham Maintains Buy on Jazz Pharmaceuticals, Lowers Price Target to $205
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia maintains a Buy rating on Jazz Pharmaceuticals (NASDAQ:JAZZ) but lowers the price target from $208 to $205.

August 01, 2024 | 12:29 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Needham analyst Ami Fadia maintains a Buy rating on Jazz Pharmaceuticals but lowers the price target from $208 to $205.
The maintained Buy rating suggests continued confidence in Jazz Pharmaceuticals' performance, but the slight reduction in the price target indicates some caution. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100